首頁 > 市場調查報告書 > 製藥

消化器

胃腸病學市場規模、佔有率和成長分析（按類型、分銷管道、應用、給藥途徑和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898399

胃腸病學市場規模、佔有率和成長分析（按類型、分銷管道、應用、給藥途徑和地區分類）—產業預測（2026-2033 年）

Gastroenterology Market Size, Share, and Growth Analysis, By Type (Branded, Generics), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies), By Application, By Route Of Administration, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球胃腸病學市場規模將達到 396.1 億美元，到 2025 年將成長至 419.4 億美元，到 2033 年將成長至 663.5 億美元，在預測期（2026-2033 年）內複合年成長率為 5.9%。

胃腸道疾病盛行率的不斷上升正在推動市場成長，這主要是由於不健康的飲食習慣和人口老化所造成的。可靠的臨床研究數量激增和醫療保健支出不斷成長也是重要的成長要素。目前，包括細胞療法和創新小分子化合物在內的多種先進療法已投入使用。胃腸道疾病導致的住院和手術干預增加進一步強化了這一趨勢，促使生物製藥公司加強對生物製劑和生物相似藥的研發投入。該領域正在進行的臨床試驗為開發有效治療方法提供了許多機遇，為胃腸道醫療保健領域的變革性進步鋪平了道路。

全球胃腸病學市場促進因素

全球胃腸病學市場受到膽結石、潰瘍性大腸炎、痔瘡、大腸激躁症(IBS) 和胃食道逆流 (GERD) 等消化系統疾病日益普遍的顯著影響。不健康的飲食習慣、久坐的生活方式、不斷上升的壓力水平、食物過敏和感染疾病等因素均導致慢性及急性胃腸道疾病發病率的上升。因此，對包括制酸劑、瀉藥、質子幫浦抑制劑和抗生素在內的各種藥物的需求不斷成長，這些藥物旨在有效控制這些疾病並減少潛在的健康併發症。治療需求的激增正在推動全球胃腸病學治療市場的成長。

限制全球胃腸病學市場的因素

由於治療費用高昂，全球胃腸病學市場可能面臨嚴峻挑戰。包括克隆氏症和潰瘍性大腸炎等慢性疾病在內的多種胃腸道疾病需要持續管理，以降低復發風險和潛在的癌症進展。治療的綜合成本主要包括藥物費用、醫療諮詢費用和住院費用。慢性胃腸道疾病的治療通常涉及生技藥品的使用，而生物製劑價格昂貴。這些高昂的自付費用預計將嚴重阻礙市場成長，並影響許多尋求治療的患者獲得治療的機會。

全球胃腸病學市場趨勢

全球胃腸病市場正經歷強勁成長，這主要得益於潰瘍性大腸炎和克隆氏症多種胃腸道疾病盛行率的上升。需求的激增促使製藥和生技公司優先投入研發，以開發新型療法。這些公司不斷擴充的研發管線表明，市場環境充滿活力，專注於解決複雜的胃腸道疾病問題。隨著相關人員加大對突破性療法的投資，預計該市場將顯著擴張。區域和全球供應商為開發最先進治療而進行的合作，進一步加速了胃腸病治療市場的成長。

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較
主要企業簡介
- 艾伯維公司（美國）
- 武田藥品工業株式會社（日本）
- 阿斯特捷利康有限公司（英國）
- 拜耳股份公司（德國）
- 輝瑞公司（美國）
- 強生公司（美國）
- 諾華公司（瑞士）
- 默克公司（美國）
- 賽諾菲公司（法國）
- 葛蘭素史克有限公司（英國）
- 勃林格殷格翰國際有限公司（德國）
- 梯瓦製藥工業股份有限公司（以色列）
- 波士頓科學公司（美國）
- 美敦力公司（愛爾蘭）
- 奧林巴斯株式會社（日本）
- 富士軟片株式會社（日本）
- 史賽克公司（美國）
- 雀巢健康科學（瑞士）
- 達能股份有限公司（法國）

結論與建議

簡介目錄

Product Code: SQSG35I2028

Global Gastroenterology Market size was valued at USD 39.61 Billion in 2024 and is poised to grow from USD 41.94 Billion in 2025 to USD 66.35 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The gastroenterology market is experiencing significant growth driven by the increasing prevalence of gastrointestinal diseases, largely attributed to unhealthy dietary habits and an aging population. Key growth factors include the surge in clinical studies yielding reliable results and escalating healthcare expenditures. There is a diverse array of advanced treatment options available, such as cellular therapies and innovative small molecules. The rise in hospitalizations and surgical interventions for gastrointestinal issues further underscores this trend, prompting biopharmaceutical firms to enhance their R&D investments in biologics and biosimilars. The ongoing clinical trials in the field present numerous opportunities for the development of effective therapies, paving the way for transformative advancements in gastroenterological care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroenterology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroenterology Market Segments Analysis

Global Gastroenterology Market is segmented by type, distribution channel, application, route of administration and region. Based on type, the market is segmented into branded and generics. Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. Based on application, the market is segmented into crohn's disease, ulcerative colitis, Gerd, IBS and others. Based on route of administration, the market is segmented into injectable and oral & others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroenterology Market

The global gastroenterology market is significantly influenced by the increasing prevalence of gastrointestinal diseases, including conditions like gallstones, ulcerative colitis, hemorrhoids, irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD). Factors such as unhealthy dietary habits, sedentary lifestyles, heightened stress levels, food sensitivities, and infections contribute to the rising incidence of both chronic and acute gastrointestinal disorders. As a result, there is a growing demand for a variety of medications, including antacids, laxatives, proton pump inhibitors, and antibiotics, aimed at effectively managing these conditions and mitigating potential health complications. This surge in treatment requirements is propelling the growth of the global therapeutics market for gastrointestinal diseases.

Restraints in the Global Gastroenterology Market

The Global Gastroenterology market is likely to encounter substantial challenges stemming from the high expenses associated with treatments. Various gastrointestinal disorders, particularly chronic conditions like Crohn's disease and ulcerative colitis, necessitate ongoing management to mitigate the risk of recurrence and potential cancer development. The comprehensive costs of therapy primarily consist of medication, healthcare provider consultations, and hospital admissions. Treatments for chronic gastrointestinal diseases often involve the administration of biologic medications, which can incur hefty expenses. These elevated out-of-pocket costs for drugs and medical procedures are expected to significantly hinder market growth, impacting accessibility for many patients seeking care.

Market Trends of the Global Gastroenterology Market

The global gastroenterology market is witnessing robust growth driven by an uptick in the prevalence of various gastrointestinal disorders, including ulcerative colitis and Crohn's disease. This surge in demand is prompting pharmaceutical and biotechnology companies to prioritize research and development efforts to innovate novel therapeutics. Enhanced pipeline expansion from these firms is indicative of a dynamic landscape focused on addressing complex gastrointestinal ailments. As stakeholders increasingly invest in groundbreaking treatments, the market is expected to experience significant expansion. The collaborative efforts of regional and global vendors in developing cutting-edge therapies are further propelling the trajectory of the gastroenterology therapeutics market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Gastroenterology Market Size by Type & CAGR (2026-2033)

Market Overview
Branded
Generics

Global Gastroenterology Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Global Gastroenterology Market Size by Application & CAGR (2026-2033)

Market Overview
Crohn's Disease
Ulcerative Colitis
Gerd
IBS
Others

Global Gastroenterology Market Size by Route Of Administration & CAGR (2026-2033)

Market Overview
Injectable
Oral & Others

Global Gastroenterology Market Size & CAGR (2026-2033)

North America (Type, Distribution Channel, Application, Route Of Administration)
- US
- Canada
Europe (Type, Distribution Channel, Application, Route Of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Distribution Channel, Application, Route Of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Distribution Channel, Application, Route Of Administration)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Distribution Channel, Application, Route Of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Limited (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olympus Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stryker Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle Health Science (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danone S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments